Inari Medical, Inc. (NASDAQ:NARI) Shares Sold by Amundi

Amundi reduced its stake in shares of Inari Medical, Inc. (NASDAQ:NARI) by 10.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 201,366 shares of the company’s stock after selling 23,076 shares during the period. Amundi owned 0.34% of Inari Medical worth $10,280,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. PNC Financial Services Group Inc. raised its holdings in Inari Medical by 5.3% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,550 shares of the company’s stock valued at $130,000 after acquiring an additional 128 shares during the last quarter. Arizona State Retirement System raised its holdings in Inari Medical by 0.9% in the 4th quarter. Arizona State Retirement System now owns 15,196 shares of the company’s stock valued at $776,000 after acquiring an additional 129 shares during the last quarter. Ieq Capital LLC raised its holdings in Inari Medical by 0.3% in the 4th quarter. Ieq Capital LLC now owns 50,198 shares of the company’s stock valued at $2,563,000 after acquiring an additional 145 shares during the last quarter. Smartleaf Asset Management LLC raised its holdings in Inari Medical by 128.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 634 shares of the company’s stock valued at $33,000 after acquiring an additional 356 shares during the last quarter. Finally, KBC Group NV raised its holdings in Inari Medical by 39.0% in the 3rd quarter. KBC Group NV now owns 1,774 shares of the company’s stock valued at $73,000 after acquiring an additional 498 shares during the last quarter. 90.98% of the stock is currently owned by institutional investors and hedge funds.

Inari Medical Stock Performance

Shares of Inari Medical stock opened at $79.97 on Friday. The company has a fifty day moving average price of $78.86 and a 200 day moving average price of $58.54. Inari Medical, Inc. has a twelve month low of $36.73 and a twelve month high of $79.99. The stock has a market cap of $4.68 billion, a price-to-earnings ratio of -59.24 and a beta of 1.02.

Analyst Ratings Changes

NARI has been the subject of a number of research analyst reports. BTIG Research restated a “neutral” rating on shares of Inari Medical in a report on Wednesday, January 8th. Robert W. Baird restated a “neutral” rating and set a $80.00 price objective (down from $81.00) on shares of Inari Medical in a report on Tuesday, January 7th. Baird R W downgraded Inari Medical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 7th. Truist Financial upped their price objective on Inari Medical from $50.00 to $63.00 and gave the stock a “hold” rating in a report on Wednesday, December 18th. Finally, William Blair restated a “market perform” rating on shares of Inari Medical in a report on Tuesday, January 7th. Twelve analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $68.00.

Insider Buying and Selling at Inari Medical

In other Inari Medical news, CEO Andrew Hykes sold 3,000 shares of the company’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $55.29, for a total value of $165,870.00. Following the completion of the transaction, the chief executive officer now directly owns 439,310 shares of the company’s stock, valued at $24,289,449.90. This represents a 0.68 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director William Hoffman sold 60,000 shares of the company’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $55.66, for a total transaction of $3,339,600.00. Following the completion of the transaction, the director now directly owns 441,233 shares of the company’s stock, valued at approximately $24,559,028.78. The trade was a 11.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 263,000 shares of company stock valued at $15,599,470 in the last ninety days. Insiders own 10.60% of the company’s stock.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.